EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0

作者：

Price, Timothy ^{[1
]}

Chawla, Sant ^{[2
]}

Falchook, Gerald ^{[3
]}

Prenen, Hans ^{[4
]}

Lugowska, Iwona ^{[5
]}

Subbiah, Vivek ^{[6
]}

Monzon, Jose ^{[7
]}

Ozawa, Yuichi ^{[8
]}

Arkenau, Tobias ^{[9
]}

Lima, Caio Rocha ^{[10
]}

Kuboki, Yasutoshi ^{[11
]}

Nishina, Tomohiro ^{[12
]}

Hui, Mun ^{[13
]}

Rasmussen, Erik ^{[14
]}

Wong, Hansen ^{[14
]}

Najmi, Saltanat ^{[14
]}

Sadraei, Nooshin ^{[14
]}

机构：

[1] Univ Adelaide, Queen Elizabeth Hosp Campus, CALHN, Woodville, SA, Australia

[2] Sarcoma Oncol Ctr, Santa Monica, CA USA

[3] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[4] Univ Hosp Antwerp, Antwerp, Belgium

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Texas MD Anderson Canc, Houston, TX USA

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Wakayama Med Univ Hosp, Wakayama, Japan

[9] Sarah Cannon Res Inst UK, London, England

[10] Wake Forest Baptist Hlth, Miami, FL USA

[11] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[13] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[14] Amgen Inc, New York, NY USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0403

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

403

引用

页码：A245 / A245

页数：1

共 50 条

[21] NOVEL QUANTITATIVE APPROACH FOR A FIRST-IN-HUMAN (FIH) DOSE IN AN ONCOLOGY SETTING FOR THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) MONOCLONAL ANTIBODY (MAB), AMG 404.
Wong, H.
Mehta, K.
Dutta, S.
Upreti, V.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S51 - S51
[22] Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
Liang, Jiaqi
Li, Ming
Sui, Qihai
Hu, Zhengyang
Bian, Yunyi
Huang, Yiwei
Zhan, Cheng
Jiang, Wei
Wang, Qun
Tan, Lijie
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1302 - +
[23] An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle
Zhao, Peng
Atanackovic, Djordje
Dong, Shuyun
Yagita, Hideo
He, Xiao
Chen, Mingnan
MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1494 - 1500
[24] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma
Metcalfe, Whitney
Anderson, Jaime
Van Anh Trinh
Hwu, Wen-Jen
DISCOVERY MEDICINE, 2015, 19 (106) : 393 - 401
[25] Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
Jove, Maria
Vilarino, Noelia
Nadal, Ernest
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S364 - S368
[26] Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
Pawlowska, Anna
Suszczyk, Dorota
Tarkowski, Rafal
Paduch, Roman
Kotarski, Jan
Wertel, Iwona
CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 9691 - 9709
[27] Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
Kitano, Shigehisa
Shimizu, Toshio
Koyama, Takafumi
Ebata, Takahiro
Iwasa, Satoru
Kondo, Shunsuke
Shimomura, Akihiko
Fujiwara, Yutaka
Yamamoto, Noboru
Paccaly, Anne
Li, Siyu
Rietschel, Petra
Sims, Tasha
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 53 - 64
[28] Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
Shigehisa Kitano
Toshio Shimizu
Takafumi Koyama
Takahiro Ebata
Satoru Iwasa
Shunsuke Kondo
Akihiko Shimomura
Yutaka Fujiwara
Noboru Yamamoto
Anne Paccaly
Siyu Li
Petra Rietschel
Tasha Sims
Cancer Chemotherapy and Pharmacology, 2021, 87 : 53 - 64
[29] A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL)
Song, Yuqin
Zhou, Keshu
Jin, Chuan
Qian, Zhengzi
Hou, Ming
Fan, Lei
Li, Fei
Ding, Kaiyang
Zhou, Hui
Li, Xiaoling
Chen, Bing
Sun, Xiuhua
Song, Xianmin
Jiang, Ming
Zhang, Qingyuan
Liu, Lihong
Yu, Guohua
Hu, Yu
Zhao, Zheng
Liu, Ligen
Xue, Hongwei
Luo, Jun
He, Bai
Jin, Xiaoping
Wang, Maxwell
Li, Baiyong
Xia, Yu
Zhu, Jun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A473 - A474
[30] Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
Iguchi, Haruo
Nogami, Naoyuki
Kozuki, Toshiyuki
Matsumoto, Toshihiko
Tamura, Kenji
Yamamoto, Noboru
Shimomura, Akihiko
Hoshino, Yuji
Michibata, Yoshiko
Nii, Masahiro
Fujiwara, Yutaka
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →